<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37686733</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>17</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>What Is the Role of Palmitoylethanolamide Co-Ultramicronized with Luteolin on the Symptomatology Reported by Patients Suffering from Long COVID? A Retrospective Analysis Performed by a Group of General Practitioners in a Real-Life Setting.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3701</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu15173701</ELocationID><Abstract><AbstractText>Long COVID is a recognized post-viral syndrome characterized by neurological, somatic and neuropsychiatric symptoms that might last for long time after SARS-CoV-2 infection. An ever-growing number of patients come to the observation of General Practitioners complaining of mild or moderate symptoms after the resolution of the acute infection. Nine General Practitioners from the Rome area (Italy) performed a retrospective analysis in order to evaluate the role of the supplementation with Palmitoylethanolamide co-ultramicronized with Luteolin (PEALUT) on neurologic and clinical symptoms reported by their patients after COVID-19 resolution. Supplementation with PEALUT helped to improve all patient-reported symptoms, especially pain, anxiety and depression, fatigue, brain fog, anosmia and dysgeusia, leading to an overall improvement in patients' health status. To our knowledge these are the first data presented on Long COVID patients collected in a territorial setting. Despite their preliminary nature, these results highlight the pathogenetic role of "non-resolving" neuroinflammation in Long COVID development and consequently the importance of its control in the resolution of the pathology and put the focus on the General Practitioner as the primary figure for early detection and management of Long COVID syndrome in a real-life setting. Future randomized, controlled, perspective clinical trials are needed to confirm this preliminary observation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pirro</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Luana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccioni</LastName><ForeName>Licia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellucci</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartolucci</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piga</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciaramaglia</LastName><ForeName>Paola Lucia</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucangeli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria Locale (ASL), Sistema Sanitario Regionale, 00012 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russo</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Anaesthesiology and Reanimation, Catholic University of Sacred Heart, 00168 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuzzocrea</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6131-3690</Identifier><AffiliationInfo><Affiliation>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evangelista</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8438-3480</Identifier><AffiliationInfo><Affiliation>Institute of Anaesthesiology and Reanimation, Catholic University of Sacred Heart, 00168 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Messina, 98166 Messina, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>KUX1ZNC9J2</RegistryNumber><NameOfSubstance UI="D047311">Luteolin</NameOfSubstance></Chemical><Chemical><RegistryNumber>6R8T1UDM3V</RegistryNumber><NameOfSubstance UI="C005958">palmidrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047311" MajorTopicYN="N">Luteolin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058005" MajorTopicYN="Y">General Practitioners</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PEALUT</Keyword><Keyword MajorTopicYN="N">anosmia</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">dysgeusia</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">pain</Keyword><Keyword MajorTopicYN="N">real-life setting</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>9</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37686733</ArticleId><ArticleId IdType="pmc">PMC10490268</ArticleId><ArticleId IdType="doi">10.3390/nu15173701</ArticleId><ArticleId IdType="pii">nu15173701</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Kessel S.A.M., Olde Hartman T.C., Lucassen P.L.B.J., van Jaarsveld C.H.M. Post-acute and Long COVID-19 symptoms in patients with mild diseases: A systematic review. Fam. Pract. 2022;39:159&#x2013;167. doi: 10.1093/fampra/cmab076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmab076</ArticleId><ArticleId IdType="pmc">PMC8414057</ArticleId><ArticleId IdType="pubmed">34268556</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A., Shaar B.A., Almamlouk R., Riaz M., Obeidat M., Obeidat Y., Gerberi D., Taha R.M., et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022;28:657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2022;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings. mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health Research  Living with COVID-19&#x2014;Second Review. A Dynamic Review of the Evidence around Ongoing COVID-19 Symptoms (Often Called Long COVID)  [(accessed on 16 May 2023)].  Available online:  https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/</Citation></Reference><Reference><Citation>Theoharides T.C., Conti P. COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome? J. Biol. Regul. Homeost. Agents. 2020;34:1633&#x2013;1636.</Citation><ArticleIdList><ArticleId IdType="pubmed">33023287</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37. doi: 10.1186/1471-2377-11-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-11-37</ArticleId><ArticleId IdType="pmc">PMC3071317</ArticleId><ArticleId IdType="pubmed">21435231</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingstone T., Taylor A.K., O&#x2019;Donnell C.A., Atherton H., Blane D.N., Chew-Graham C.A. Finding the &#x2018;right&#x2019; GP: A qualitative study of the experiences of people with Long COVID. BJGP Open. 2020;4:bjgpopen20X101143. doi: 10.3399/bjgpopen20X101143.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgpopen20X101143</ArticleId><ArticleId IdType="pmc">PMC7880173</ArticleId><ArticleId IdType="pubmed">33051223</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeria M., Cejudo J.C., Sotoca J., Deus J., Krupinski J. Cognitive profile following COVID-19 infection: Clinical predictors leading to neuropsychological impairment. Brain Behav. Immun. Health. 2020;9:100163. doi: 10.1016/j.bbih.2020.100163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2020.100163</ArticleId><ArticleId IdType="pmc">PMC7581383</ArticleId><ArticleId IdType="pubmed">33111132</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Albanese M., Marrone G., Di Lauro M., Pietroboni Zaitseva A., Palazzetti D., Guerriero C., Paolino A., Pizzenti G., Di Daniele F., et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals. 2021;14:336. doi: 10.3390/ph14040336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14040336</ArticleId><ArticleId IdType="pmc">PMC8067485</ArticleId><ArticleId IdType="pubmed">33917573</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Ackerley M.B., Bluestein L.S., Brewer J.H., Brook J.B., Buchanan A.D., Cuni J.R., Davey W.P., Dempsey T.T., Dorff S.R., et al. Diagnosis of mast cell activation syndrome: A global &#x201c;consensus-2&#x201d;. Diagnosis. 2020;8:137&#x2013;152. doi: 10.1515/dx-2020-0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/dx-2020-0005</ArticleId><ArticleId IdType="pubmed">32324159</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannetti A., Filice E., Caffarelli C., Ricci G., Pession A. Mast Cell Activation Disorders. Medicina. 2021;57:124. doi: 10.3390/medicina57020124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicina57020124</ArticleId><ArticleId IdType="pmc">PMC7911219</ArticleId><ArticleId IdType="pubmed">33573161</ArticleId></ArticleIdList></Reference><Reference><Citation>Xanthos D.N., Sandk&#xfc;hler J. Neurogenic neuroinflammation: Inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 2014;15:43&#x2013;53. doi: 10.1038/nrn3617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3617</ArticleId><ArticleId IdType="pubmed">24281245</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti P. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: A promising inhibitory strategy. J. Biol. Regul. Homeost. Agents. 2020;34:1971&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">33016027</ArticleId></ArticleIdList></Reference><Reference><Citation>Steardo L., Steardo L., Jr., Zorec R., Verkhratsky A. Neuroinfection may potentially contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol. 2020;229:e13473. doi: 10.1111/apha.13473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13473</ArticleId><ArticleId IdType="pmc">PMC7228251</ArticleId><ArticleId IdType="pubmed">32223077</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Zhong S., Liu J., Li L., Li Y., Wu X., Li Z., Deng P., Zhang J., Zhong N., et al. Detection of severe acute respiratory syndrome coronavirus in the brain: Potential role of the chemokine mig in pathogenesis. Clin. Infect. Dis. 2015;41:1089&#x2013;1096. doi: 10.1086/444461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/444461</ArticleId><ArticleId IdType="pmc">PMC7107994</ArticleId><ArticleId IdType="pubmed">16163626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gigante A., Aquili A., Farinelli L., Caraffa A., Ronconi G., Gallenga C.E., Tet&#xe8; G., Kritas S.K., Conti P. Sodium Chromo-Glycate and Palmitoylethanolamide: A Possible Strategy to Treat Mast Cellinduced Lung Inflammation in COVID-19. Med. Hypotheses. 2020;143:109856. doi: 10.1016/j.mehy.2020.109856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109856</ArticleId><ArticleId IdType="pmc">PMC7236677</ArticleId><ArticleId IdType="pubmed">32460208</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.H., Wang Y.R., Wang Q.H., Chen Y., Chen X., Li Y., Cen Y., Xu C., Hu T., Liu X.D., et al. Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Mol. Neurodegener. 2021;16:48. doi: 10.1186/s13024-021-00469-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00469-w</ArticleId><ArticleId IdType="pmc">PMC8287105</ArticleId><ArticleId IdType="pubmed">34281568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansell V., Hall Dykgraaf S., Kidd M., Goodyear-Smith F. Long COVID and older people. Lancet Healthy Longev. 2022;3:e849&#x2013;e854. doi: 10.1016/S2666-7568(22)00245-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(22)00245-8</ArticleId><ArticleId IdType="pubmed">36480981</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Klein S.L., Garibaldi B.T., Li H., Wu C., Osevala N.M., Li T., Margolick J.B., Pawelec G., Leng S.X. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res. Rev. 2021;65:101205. doi: 10.1016/j.arr.2020.101205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloe L., Leon A., Levi-Montalcini R. A proposed autacoidmechanism controlling mastocyte behaviour. Agents Actions. 1993;39:145&#x2013;147. doi: 10.1007/BF01972748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01972748</ArticleId><ArticleId IdType="pubmed">7505999</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Schiano Moriello A., Cerrato S., Fusco M., Puigdemont A., De Petrocellis L., Di Marzo V. The anti-inflammatory mediator palmitoylethanolamide enhances the levels of 2-arachidonoyl-glycerol and potentiates its actions at transient receptor potential vanilloid type-1 channels. Br. J. Pharmacol. 2016;173:1154&#x2013;1162. doi: 10.1111/bph.13084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13084</ArticleId><ArticleId IdType="pmc">PMC5338153</ArticleId><ArticleId IdType="pubmed">25598150</ArticleId></ArticleIdList></Reference><Reference><Citation>Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differentialsensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 1995;92:3376&#x2013;3380. doi: 10.1073/pnas.92.8.3376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.8.3376</ArticleId><ArticleId IdType="pmc">PMC42169</ArticleId><ArticleId IdType="pubmed">7724569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerrato S., Brazis P., della Valle M.F., Miolo A., Puigdemont A. Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells. Vet. Immunol. Immunopathol. 2010;133:9&#x2013;15. doi: 10.1016/j.vetimm.2009.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetimm.2009.06.011</ArticleId><ArticleId IdType="pubmed">19625089</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Fusco M., Della Valle M.F., Zusso M., Costa B., Giusti P. Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology. 2014;22:79&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">24178954</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Zusso M., Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front. Cell. Neurosci. 2018;12:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5871676</ArticleId><ArticleId IdType="pubmed">29618972</ArticleId></ArticleIdList></Reference><Reference><Citation>Beggiato S., Tomasini M.C., Cassano T., Ferraro L. Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer&#x2019;s Disease. J. Clin. Med. 2020;9:428. doi: 10.3390/jcm9020428.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020428</ArticleId><ArticleId IdType="pmc">PMC7074257</ArticleId><ArticleId IdType="pubmed">32033363</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Cordaro M., Verde R., Schiano Moriello A., Marcolongo G., Schievano C., Siracusa R., Piscitelli F., Peritore A.F., Crupi R., et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol. 2018;9:249. doi: 10.3389/fphar.2018.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2018.00249</ArticleId><ArticleId IdType="pmc">PMC5870042</ArticleId><ArticleId IdType="pubmed">29615912</ArticleId></ArticleIdList></Reference><Reference><Citation>Impellizzeri D., Bruschetta G., Cordaro M., Crupi R., Siracusa R., Esposito E., Cuzzocrea S. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. J. Neuroinflammation. 2014;28:136. doi: 10.1186/s12974-014-0136-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0136-0</ArticleId><ArticleId IdType="pmc">PMC4171547</ArticleId><ArticleId IdType="pubmed">25164769</ArticleId></ArticleIdList></Reference><Reference><Citation>Crupi R., Impellizzeri D., Cordaro M., Siracusa R., Casili G., Evangelista M., Cuzzocrea S. N-palmitoylethanolamide Prevents Parkinsonian Phenotypes in Aged Mice. Mol. Neurobiol. 2018;55:8455&#x2013;8472. doi: 10.1007/s12035-018-0959-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0959-2</ArticleId><ArticleId IdType="pubmed">29552727</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco R., Gugliandolo E., Campolo M., Evangelista M., Di Paola R., Cuzzocrea S. Effect of a new formulation of micronized and ultramicronized N-palmitoylethanolamine in a tibia fracture mouse model of complex regional pain syndrome. PLoS ONE. 2017;12:e0178553. doi: 10.1371/journal.pone.0201501. Erratum in: PLoS ONE 2018, 13, e0201501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0201501</ArticleId><ArticleId IdType="pmc">PMC5464592</ArticleId><ArticleId IdType="pubmed">28594885</ArticleId></ArticleIdList></Reference><Reference><Citation>Impellizzeri D., Peritore A.F., Cordaro M., Gugliandolo E., Siracusa R., Crupi R., D&#x2019;Amico R., Fusco R., Evangelista M., Cuzzocrea S., et al. The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice. FASEB J. 2019;33:11364&#x2013;11380. doi: 10.1096/fj.201900538R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201900538R</ArticleId><ArticleId IdType="pubmed">31344333</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa R., Fusco R., Cordaro M., Peritore A.F., D&#x2019;Amico R., Gugliandolo E., Crupi R., Genovese T., Evangelista M., Di Paola R., et al. The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats. Int. J. Mol. Sci. 2020;21:7700. doi: 10.3390/ijms21207700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21207700</ArticleId><ArticleId IdType="pmc">PMC7589788</ArticleId><ArticleId IdType="pubmed">33080989</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelista M., Cilli V., De Vitis R., Militerno A., Fanfani F. Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study. CNS Neurol. Disord. Drug Targets. 2018;17:291&#x2013;298. doi: 10.2174/1871527317666180420143830.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527317666180420143830</ArticleId><ArticleId IdType="pubmed">29676237</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Schiano Moriello A. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review. Int. J. Mol. Sci. 2020;21:9526. doi: 10.3390/ijms21249526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21249526</ArticleId><ArticleId IdType="pmc">PMC7765232</ArticleId><ArticleId IdType="pubmed">33333772</ArticleId></ArticleIdList></Reference><Reference><Citation>Colizzi M., Bortoletto R., Colli C., Bonomo E., Pagliaro D., Maso E., Di Gennaro G., Balestrieri M. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence. Front. Psychiatry. 2022;13:1038122. doi: 10.3389/fpsyt.2022.1038122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2022.1038122</ArticleId><ArticleId IdType="pmc">PMC9650099</ArticleId><ArticleId IdType="pubmed">36387000</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolfo E., Cutuli D., Petrosini L., Caltagirone C. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules. 2022;12:667. doi: 10.3390/biom12050667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12050667</ArticleId><ArticleId IdType="pmc">PMC9138306</ArticleId><ArticleId IdType="pubmed">35625595</ArticleId></ArticleIdList></Reference><Reference><Citation>Scuteri D., Guida F., Boccella S., Palazzo E., Maione S., Rodr&#xed;guez-Landa J.F., Mart&#xed;nez-Mota L., Tonin P., Bagetta G., Corasaniti M.T. Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence. Pharmaceutics. 2022;14:1672. doi: 10.3390/pharmaceutics14081672.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14081672</ArticleId><ArticleId IdType="pmc">PMC9414729</ArticleId><ArticleId IdType="pubmed">36015298</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese M., Marrone G., Paolino A., Di Lauro M., Di Daniele F., Chiaramonte C., D&#x2019;Agostini C., Romani A., Cavaliere A., Guerriero C., et al. Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case-Control Study. Pharmaceuticals. 2022;15:253. doi: 10.3390/ph15020253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15020253</ArticleId><ArticleId IdType="pmc">PMC8878249</ArticleId><ArticleId IdType="pubmed">35215365</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Di Marzo V. The pharmacology of Palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br. J. Pharmacol. 2017;174:1349&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5429331</ArticleId><ArticleId IdType="pubmed">27539936</ArticleId></ArticleIdList></Reference><Reference><Citation>Peritore A.F., Siracusa R., Crupi R., Cuzzocrea S. Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets. Nutrients. 2019;11:2175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6769461</ArticleId><ArticleId IdType="pubmed">31514292</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola R., Fusco R., Gugliandolo E., Crupi R., Evangelista M., Granese R., Cuzzocrea S. Co-micronized Palmitoylethanolamide/Polydatin Treatment Causes Endometriotic Lesion Regression in a Rodent Model of Surgically Induced Endometriosis. Front. Pharmacol. 2016;7:382. doi: 10.3389/fphar.2016.00382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2016.00382</ArticleId><ArticleId IdType="pmc">PMC5063853</ArticleId><ArticleId IdType="pubmed">27790149</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterniti I., Impellizzeri D., Di Paola R., Navarra M., Cuzzocrea S., Esposito E. A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury. J. Neuroinflamm. 2013;23:91. doi: 10.1186/1742-2094-10-91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-91</ArticleId><ArticleId IdType="pmc">PMC3728012</ArticleId><ArticleId IdType="pubmed">23880066</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordaro M., Impellizzeri D., Paterniti I., Bruschetta G., Siracusa R., De Stefano D., Cuzzocrea S., Esposito E. Neuroprotective effects of PEALUT on secondary inflammatory process and autophagy involved in traumatic brain injury. J. Neurotrauma. 2016;33:132&#x2013;146. doi: 10.1089/neu.2014.3460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3460</ArticleId><ArticleId IdType="pubmed">25046306</ArticleId></ArticleIdList></Reference><Reference><Citation>Siracusa R., Impellizzeri D., Cordaro M., Crupi R., Esposito E., Petrosino S., Cuzzocrea S. Anti-inflammatory and neuroprotective effects of PEALUT in a mouse model of vascular dementia. Front. Neurol. 2017;8:233. doi: 10.3389/fneur.2017.00233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00233</ArticleId><ArticleId IdType="pmc">PMC5460147</ArticleId><ArticleId IdType="pubmed">28634464</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., Vaira L.A., Cantone E., De Luca P., Cingolani C., Motta G., De Riu G., Vitelli F., Spriano G., et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial. Curr. Neuropharmacol. 2022;20:2001&#x2013;2012. doi: 10.2174/1570159X20666220420113513.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascanio L., Vitelli F., Cingolani C., Maranzano M., Brenner M.J., Di Stadio A. Randomized clinical trial &#x201c;olfactory dysfunction after COVID-19: Olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin&#x201d;: Preliminary results. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4156&#x2013;4162.</Citation><ArticleIdList><ArticleId IdType="pubmed">34156697</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Camaioni A., Marra P., Salzano G., Carriere G., Ricciardi L., Pucci R., Montemurro N., Brenner M.J., Di Stadio A. Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells. 2022;11:2552. doi: 10.3390/cells11162552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11162552</ArticleId><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="pubmed">36010630</ArticleId></ArticleIdList></Reference><Reference><Citation>Versace V., Ortelli P., Dezi S., Ferrazzoli D., Alibardi A., Bonini I., Engl M., Maestri R., Assogna M., Ajello V., et al. Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABAB-ergic activity and cortical plasticity in long COVID-19 syndrome. Clin. Neurophysiol. 2023;145:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9650483</ArticleId><ArticleId IdType="pubmed">36455453</ArticleId></ArticleIdList></Reference><Reference><Citation>Freynhagen R., T&#xf6;lle T.R., Gockel U., Baron R. The painDETECT project&#x2014;Far more than a screening tool on neuropathic pain. Curr. Med. Res Opin. 2016;32:1033&#x2013;1057. doi: 10.1185/03007995.2016.1157460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007995.2016.1157460</ArticleId><ArticleId IdType="pubmed">26907456</ArticleId></ArticleIdList></Reference><Reference><Citation>Haefeli M., Elfering A. Pain assessment. Eur. Spine J. 2006;15:17&#x2013;24. doi: 10.1007/s00586-005-1044-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-005-1044-x</ArticleId><ArticleId IdType="pmc">PMC3454549</ArticleId><ArticleId IdType="pubmed">16320034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp R. The Hamilton Rating Scale for Depression. Occup. Med. 2015;65:340. doi: 10.1093/occmed/kqv043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqv043</ArticleId><ArticleId IdType="pubmed">25972613</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E. Hamilton Rating Scale for Anxiety (HAM-A) Occup. Med. 2015;65:601. doi: 10.1093/occmed/kqv054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/occmed/kqv054</ArticleId><ArticleId IdType="pubmed">26370845</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Cholevas C., Polyzoidis K., Politis A. Long COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. Biofactors. 2021;47:232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Raciti L., De Luca R., Raciti G., Arcadi F.A., Calabr&#xf2; R.S. The Use of Palmitoylethanolamide in the Treatment of Long COVID: A Real-Life Retrospective Cohort Study. Med. Sci. 2022;10:37. doi: 10.3390/medsci10030037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci10030037</ArticleId><ArticleId IdType="pmc">PMC9326613</ArticleId><ArticleId IdType="pubmed">35893119</ArticleId></ArticleIdList></Reference><Reference><Citation>Busner J., Targum S.D. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiaty. 2007;4:28&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880930</ArticleId><ArticleId IdType="pubmed">20526405</ArticleId></ArticleIdList></Reference><Reference><Citation>Rampakakis E., Ste-Marie P.A., Sampalis J.S., Karellis A., Shir Y., Fitzcharles M.A. Real-life assessment of the validity of patient global impression of change in fibromyalgia. RMD Open. 2015;1:e000146. doi: 10.1136/rmdopen-2015-000146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2015-000146</ArticleId><ArticleId IdType="pmc">PMC4623367</ArticleId><ArticleId IdType="pubmed">26535150</ArticleId></ArticleIdList></Reference><Reference><Citation>Is &#x2018;long COVID&#x2019; Worsening the Labor Shortage?  [(accessed on 16 May 2013)].  Available online:  https://www.brookings.edu/articles/is-long-covid-worsening-the-labor-shortage/</Citation></Reference><Reference><Citation>The Economic Cost of Long COVID: An Update&#x2014;David Cutler.  [(accessed on 16 May 2023)].  Available online:  https://www.hks.harvard.edu/centers/mrcbg/programs/growthpolicy/economic-cost-long-covid-update-david-cutler.</Citation></Reference><Reference><Citation>We Need an Operation Warp Speed for Long COVID.  [(accessed on 16 May 2023)].  Available online:  https://www.scientificamerican.com/article/we-need-an-operation-warp-speed-for-long-covid/</Citation></Reference><Reference><Citation>Spudich S., Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267&#x2013;269. doi: 10.1126/science.abm2052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo P., Benito Ballesteros A., Yeung S.P., Liu R., Saha A., Curtis L., Kaser M., Haggard M.P., Cheke L.G. COVCOG 2: Cognitive and Memory Deficits in Long COVID: A Second Publication From the COVID and Cognition Study. Front. Aging Neurosci. 2022;14:804937. doi: 10.3389/fnagi.2022.804937.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.804937</ArticleId><ArticleId IdType="pmc">PMC8967943</ArticleId><ArticleId IdType="pubmed">35370620</ArticleId></ArticleIdList></Reference><Reference><Citation>Raciti L., Arcadi F.A., Calabr&#xf2; R.S. Could Palmitoylethanolamide Be an Effective Treatment for Long COVID-19? Hypothesis and Insights in Potential Mechanisms of Action and Clinical Applications. Innov. Clin. Neurosci. 2022;19:19&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970234</ArticleId><ArticleId IdType="pubmed">35382075</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D.R., Al-Jabr H., Windle K., Ski C.F. Long COVID: Supporting people through the quagmire. Br. J. Gen Pract. 2021;71:561. doi: 10.3399/bjgp21X717917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3399/bjgp21X717917</ArticleId><ArticleId IdType="pmc">PMC8686427</ArticleId><ArticleId IdType="pubmed">34824074</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie C.E., Lowe D.J., McAuley A., Mills N.L., Winter A.J., Black C., Scott J.T., O&#x2019;Donnell C.A., Blane D.N., Browne S., et al. Natural history of Long COVID in a nationwide, population cohort study. Nat. Commun. 2023;14:3504. doi: 10.1038/s41467-023-39193-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39193-y</ArticleId><ArticleId IdType="pmc">PMC10263377</ArticleId><ArticleId IdType="pubmed">37311808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>